Diabetes

20
Sep

Diabetes Drug Reducing Heart Risks

Jardiance (Empagliflozin) for Type 2 Diabetes Mellitus Patients Jardiance (Empagliflozin) The drug “Jardiance” was approved by the US FDA on August 1, 2014 (see below). JARDIANCE tablets contain empagliflozin, an orally-active inhibitor of the sodium-glucose co-transporter 2 (SGLT2). The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S).  Its molecular formula is C23H27ClO7 and the molecular weight is 450.91. The structural formula is:

Read more

29
Oct

For Diabetes: Physical Activity – Practical Tips and Action Steps Video

[Educational Video] Preventing Type 2 Diabetes Video

27
Oct

Glucose Lowering Drugs, DPP-4i, Linked to Lowering the Risk of Autoimmune Diseases

By Admin; LinkedIn; Google Plus; Twitter Glucose Lowering Drugs, DPP-4i, Linked to Lowering the Risk of Autoimmune Diseases Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes May Reduce The Risk Of Autoimmune Diseases. By Kim, Seoyoung C., Schneeweiss, Sebastian, Glynn, Robert J., Doherty, Michael, Goldfine, Allison, Solomon, Daniel H.; Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes May Reduce The Risk Of Autoimmune Diseases. [abstract]. Arthritis

Read more

3
Oct

Webcasts 2013 European Association for the Study of Diabetes

European Association for the Study of Diabetes (EASD) The mission of EASD is to promote excellence in diabetes care through research and education The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. To know more about EASD, click here. 2013 EASD Meeting 49TH ANNUAL

Read more

26
Jul

EMA Investigation into GLP-1 Based Diabetes Therapies Concluded: No New Concerns

EU EMA CHMP Investigation into GLP-1 based diabetes therapies concluded: No New Concerns  JUL-27-2013 No new concerns for GLP-1 therapies identified on the basis of available evidence The European Medicines Agency’s Committee for Medicinal Products for Human Use(CHMP) has finalised a review of GLP-1-based diabetes therapies. The Committee concluded that presently available data do not confirm recent concerns over an increased

Read more

14
Jun

The BMJ Investigation From the Monsters Mouth

From the monster’s mouth: has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? By Dr. David Lim, Ph.D., RAC, ASQ-CQA (LinkedIn) Incretin mimetics have been called “the darlings of diabetes treatment” and they may soon also be licensed for treating obesity. But a BMJ investigation has found growing safety concerns linked to the drugs’ mechanism of action. Deborah Cohen

Read more